|
|
 |
 |
| |
 Version imprimable |
Interest of PS100 assay when 99mTc sestamibi scintigraphy failed to identify lymph node metastases of melanoma |
European Journal of Dermatology. Volume 11, Numéro 5, 432-5, September - October 2001, Revues
|
 Free Article
Summary
|
Auteur(s) : Anne AUGUSSEAU-CAILLOT, Claude SOLER, Franck TEYSSIER, Jean-Luc PERROT, Olivier TIFFET, Frédérique CAMBAZARD, Jacques CUILLERET, Jean-Marc DUMOLLARD |
Résumé : The study evaluated the contribution of serum PS100 assay to the detection of lymph node metastases during the follow-up of patients previously treated for a malignant melanoma, in addition to 99mTc sestamibi (MIBI) scintigraphy and investigation for gene MDR1, in order to detect chemoresistance phenomena. The study included 37 patients with a clinically questionable lymph node around basin lymphatic areas of the previously surgically-treated malignant melanoma. The sensitivity and specificity of PS100 assay were 91% and 86.5%, respectively. The sensitivity and specificity of MIBI scintigraphy were 95% and 85%, respectively. Overexpression of gene MDR1 was observed in six cases. In the event of negative scintigraphic findings, the concomitant analysis of PS100 levels and the scintigraphic result enabled the metastatic MDR+ patients to be distinguished from the non-metastatic patients. PS100 assay may therefore be proposed for the follow-up of malignant melanoma. |
Mots-clés : protein S-100, 99mTc MIBI, malignant melanoma, lymph node, metastases, chemoresistance |
|
